Notification of Neuren investor webinar on 12 February 2026
Released
Released
Announcement PDF
Neuren (NEU) – ASX Announcement 11 February 2026
Neuren Investor Webinar on 12 February 2026
Investor Webinar | Thursday, 12 Feb 2026 at 10.30 AM AEDT
You are invited to register using this link:
https://us06web.zoom.us/webinar/register/WN_PAmRjBeJQQeUn-FItCmGAg
Participants may submit questions at registration or during the session
Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) management will host an investor webinar
on Thursday, 12 February 2026 at 10:30 AM Australian Eastern Daylight Time to discuss Neuren’s
recently announced business updates. Registration for the webinar may be completed via the link above.
About Neuren
Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in
early childhood and have no or limited approved treatment options.
DAYBUE® (trofinetide) and DAYBUE STIX (trofinetide) are approved by the US Food and Drug
Administration (FDA) for the treatment of Rett syndrome. Neuren has granted an exclusive worldwide
licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide.
Neuren’s second drug candidate, NNZ-2591, is in development for multiple neurodevelopmental
disorders, with a Phase 3 clinical trial in Phelan-McDermid syndrome ongoing and positive results
achieved in Phase 2 clinical trials in Pitt Hopkins syndrome and Angelman syndrome. Recognising the
urgent unmet need, each program has been granted “orphan drug” designation in the United States and
the European Union. Orphan drug designation provides incentives to encourage development of
therapies for rare and serious diseases.
Contact:
investorrelations@neurenpharma.com
Jon Pilcher, CEO: +61 438 422 271
ASX Listing Rules information
This announcement was authorized to be given to the ASX by the Board of Neuren Pharmaceuticals
Limited, Suite 1.01, 117 Camberwell Road, Hawthorn East, VIC 3123
Forward-looking Statements
This announcement contains forward-looking statements that are subject to risks and uncertainties. Such
statements involve known and unknown risks and important factors that may cause the actual results,
performance or achievements of Neuren to be materially different from the statements in this
announcement.
Share your feedback
Discover